Josée Golay, Greta Ubiali, Martino Introna. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica 2017;102(10):e400-e403; https://doi.org/10.3324/haematol.2017.169334.